374 related articles for article (PubMed ID: 29085224)
1. Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis.
Iyer JK; Kalra M; Kaul A; Payton ME; Kaul R
World J Gastroenterol; 2017 Oct; 23(37):6802-6816. PubMed ID: 29085224
[TBL] [Abstract][Full Text] [Related]
2. The clinical and pathogenetic significance of estrogen receptor-beta expression in chronic liver diseases and liver carcinoma.
Iavarone M; Lampertico P; Seletti C; Francesca Donato M; Ronchi G; del Ninno E; Colombo M
Cancer; 2003 Aug; 98(3):529-34. PubMed ID: 12879470
[TBL] [Abstract][Full Text] [Related]
3. Aberrant estrogen receptor alpha expression correlates with hepatocellular carcinoma metastasis and its mechanisms.
Sheng ML; Xu GL; Zhang CH; Jia WD; Ren WH; Liu WB; Zhou T; Wang YC; Lu ZL; Liu WF; Dong XZ; Wang XJ; Lv Y
Hepatogastroenterology; 2014; 61(129):146-50. PubMed ID: 24895811
[TBL] [Abstract][Full Text] [Related]
4. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver.
Masaki T; Tokuda M; Yoshida S; Nakai S; Morishita A; Uchida N; Funaki T; Kita Y; Funakoshi F; Nonomura T; Himoto T; Deguchi A; Kimura Y; Izuishi K; Wakabayashi H; Usuki H; Yoshiji H; Watanabe S; Kurokohchi K; Kuriyama S
Int J Oncol; 2005 Mar; 26(3):661-71. PubMed ID: 15703821
[TBL] [Abstract][Full Text] [Related]
5. Menatetrenone, a vitamin K2 analogue, inhibits hepatocellular carcinoma cell growth by suppressing cyclin D1 expression through inhibition of nuclear factor kappaB activation.
Ozaki I; Zhang H; Mizuta T; Ide Y; Eguchi Y; Yasutake T; Sakamaki T; Pestell RG; Yamamoto K
Clin Cancer Res; 2007 Apr; 13(7):2236-45. PubMed ID: 17404108
[TBL] [Abstract][Full Text] [Related]
6. Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation.
Teng J; Wang ZY; Jarrard DF; Bjorling DE
Endocr Relat Cancer; 2008 Mar; 15(1):351-64. PubMed ID: 18310301
[TBL] [Abstract][Full Text] [Related]
7. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma.
Tai DI; Tsai SL; Chang YH; Huang SN; Chen TC; Chang KS; Liaw YF
Cancer; 2000 Dec; 89(11):2274-81. PubMed ID: 11147598
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry panel segregates molecular types of hepatocellular carcinoma in Brazilian autopsy cases.
Felipe-Silva A; Wakamatsu A; Dos Santos Cirqueira C; Alves VA
World J Gastroenterol; 2016 Jul; 22(27):6246-56. PubMed ID: 27468214
[TBL] [Abstract][Full Text] [Related]
9. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
[TBL] [Abstract][Full Text] [Related]
10. Interferon regulatory factor 5 (IRF5) suppresses hepatitis C virus (HCV) replication and HCV-associated hepatocellular carcinoma.
Cevik O; Li D; Baljinnyam E; Manvar D; Pimenta EM; Waris G; Barnes BJ; Kaushik-Basu N
J Biol Chem; 2017 Dec; 292(52):21676-21689. PubMed ID: 29079574
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor subtype agonist activation in human cutaneous squamous cell carcinoma cells modulates expression of CD55 and Cyclin D1.
Lan J; Gao XH; Kaul R
EXCLI J; 2019; 18():606-618. PubMed ID: 31611744
[TBL] [Abstract][Full Text] [Related]
12. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor levels and lipid peroxidation in hepatocellular carcinoma with hepatitis C virus infection.
Shimizu I; Inoue H; Yano M; Shinomiya H; Wada S; Tsuji Y; Tsutsui A; Okamura S; Shibata H; Ito S
Liver; 2001 Oct; 21(5):342-9. PubMed ID: 11589771
[TBL] [Abstract][Full Text] [Related]
14. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-β.
Li HP; Zeng XC; Zhang B; Long JT; Zhou B; Tan GS; Zeng WX; Chen W; Yang JY
Carcinogenesis; 2013 Nov; 34(11):2443-51. PubMed ID: 23740840
[TBL] [Abstract][Full Text] [Related]
15. Activation of estrogen receptors with E2 downregulates peroxisome proliferator-activated receptor γ in hepatocellular carcinoma.
Lin YM; Velmurugan BK; Yeh YL; Tu CC; Ho TJ; Lai TY; Tsai CH; Tsai FJ; Tsai CH; Huang CY
Oncol Rep; 2013 Dec; 30(6):3027-31. PubMed ID: 24126791
[TBL] [Abstract][Full Text] [Related]
16. Serum Beta-2 Microglobulin: a Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related Liver Diseases.
Ouda SM; Khairy AM; Sorour AE; Mikhail MN
Asian Pac J Cancer Prev; 2015; 16(17):7825-9. PubMed ID: 26625805
[TBL] [Abstract][Full Text] [Related]
17. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C.
Dutta U; Kench J; Byth K; Khan MH; Lin R; Liddle C; Farrell GC
Hum Pathol; 1998 Nov; 29(11):1279-84. PubMed ID: 9824107
[TBL] [Abstract][Full Text] [Related]
19. Association of genetic polymorphism of BCL-2 (rs2279115) with susceptibility to HCV-related hepatocellular carcinoma.
Ahmed HS; Wahab EA; Elhady HA; Elgerby MM
Immunol Res; 2020 Aug; 68(4):189-197. PubMed ID: 32623689
[TBL] [Abstract][Full Text] [Related]
20. Estrogen, estrogen receptors, and hepatocellular carcinoma: Are we there yet?
Sukocheva OA
World J Gastroenterol; 2018 Jan; 24(1):1-4. PubMed ID: 29358876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
